Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NELIA ESTHER SANCHEZ-CRESPO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1790990851
CMS profile
699626
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$728.73

30 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $728.73 30

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NELIA ESTHER SANCHEZ-CRESPO

NPI 1790990851 · CMS profile ID 699626

Allopathic & Osteopathic Physicians / Internal Medicine

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790990851?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790990851?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790990851?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–30 of 30 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1790990851?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

30 matching records · $728.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 30 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–30 of 30.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $34.4812/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238629709 CMS
Eisai Inc. $16.9112/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244502406 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.7612/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225766734 CMS
Astellas Pharma US Inc $19.3611/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238580027 CMS
Kowa Pharmaceuticals America, Inc. $14.0411/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243117688 CMS
AstraZeneca Pharmaceuticals LP $22.9011/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206469581 CMS
AstraZeneca Pharmaceuticals LP $23.3010/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207078553 CMS
Exact Sciences Corporation $17.4210/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235577946 CMS
ViiV Healthcare Company $32.9409/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189597428 CMS
PFIZER INC. $18.2509/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229170669 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.6908/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225766731 CMS
Exact Sciences Corporation $17.9608/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235577942 CMS
Novo Nordisk Inc $23.8308/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188341897 CMS
PFIZER INC. $21.6308/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229261293 CMS
AstraZeneca Pharmaceuticals LP $22.5708/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207251793 CMS
Novo Nordisk Inc $20.7007/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188313908 CMS
Lilly USA, LLC $18.5706/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186840529 CMS
Medtronic, Inc. $65.0505/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219054936 CMS
AstraZeneca Pharmaceuticals LP $19.2905/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207076131 CMS
AstraZeneca Pharmaceuticals LP $23.3004/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206804026 CMS
Lilly USA, LLC $29.1704/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186816693 CMS
Hologic Sales and Service, LLC $32.4903/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182593795 CMS
Hologic Sales and Service, LLC $37.2403/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182593779 CMS
Novo Nordisk Inc $17.0703/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188825717 CMS
ViiV Healthcare Company $22.2503/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189604703 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.8202/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225766727 CMS
Exact Sciences Corporation $24.4402/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235577937 CMS
AstraZeneca Pharmaceuticals LP $22.1802/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207171245 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.3301/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225766723 CMS
Exact Sciences Corporation $27.7901/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235577933 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $519.24 8
PY2020 $173.44 11
PY2021 $252.44 16
PY2022 $281.68 15
PY2023 $2,585.02 22
PY2024 $2,063.21 35
PY2025 $728.73 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,652,523.02 227
PY2024 Principal investigator $7,882,760.60 649
PY2023 Principal investigator $10,990,435.50 4,306
PY2022 Principal investigator $2,420,977.88 1,673
PY2021 Principal investigator $723,239.31 8
PY2020 Principal investigator $1,155,430.22 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

649 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171237
Principal investigator 1 Merck Sharp & Dohme LLC $5,407.20 12/31/2024 Non-covered Recipient Entity
Research Centers of America Hollywood
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation C in Healthy Adults No dispute reported 06/30/2026 1136437652
Principal investigator 1 PFIZER INC. $9,010.17 12/31/2024 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1130953257
Principal investigator 1 PFIZER INC. $24,931.94 12/31/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130964432
Principal investigator 1 PFIZER INC. $41,296.58 12/27/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130953262
Principal investigator 1 SANOFI PASTEUR INC. $445.50 12/27/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128702052
Principal investigator 1 ModernaTX, Inc. $6,123.60 12/23/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153449
Principal investigator 1 ModernaTX, Inc. $122,010.30 12/23/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147181525
Principal investigator 1 PFIZER INC. $3,465.45 12/20/2024 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1130953048
Principal investigator 1 ModernaTX, Inc. $118,471.30 12/19/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153445
Principal investigator 1 ModernaTX, Inc. $297,767.70 12/19/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147181517
Principal investigator 1 PFIZER INC. $133,004.47 12/17/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130953054
Principal investigator 1 ModernaTX, Inc. $6,579.04 12/13/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153443
Principal investigator 1 ModernaTX, Inc. $5,370.00 12/13/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1147153447
Principal investigator 1 ABBVIE INC. $715.50 12/12/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson s Disease No dispute reported 06/30/2026 1100761291
Principal investigator 1 ABBVIE INC. $1,053.50 12/12/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson s Disease No dispute reported 06/30/2026 1100761293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 12/11/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,586.00 12/11/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $750.00 12/11/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148079
Principal investigator 1 PFIZER INC. $14.10 12/10/2024 Non-covered Recipient Entity
Research Centers of America Hollywood
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130919980
Principal investigator 1 SANOFI PASTEUR INC. $1,088.78 12/09/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1128702046
Principal investigator 1 SANOFI PASTEUR INC. $1,750.00 12/09/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1128702048
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 12/05/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171235
Principal investigator 1 SANOFI PASTEUR INC. $354,393.90 12/05/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1128702040
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 12/04/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148081
Principal investigator 1 PFIZER INC. $43,562.47 12/04/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130953251
Principal investigator 1 SANOFI PASTEUR INC. $211,755.98 12/04/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128702038
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171427
Principal investigator 1 SANOFI PASTEUR INC. $12,450.00 11/28/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1128702058
Principal investigator 1 ModernaTX, Inc. $82,194.34 11/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153435
Principal investigator 1 ModernaTX, Inc. $1,504.17 11/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153437
Principal investigator 1 ModernaTX, Inc. $81,926.10 11/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153441
Principal investigator 1 ModernaTX, Inc. $118,264.50 11/27/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147181505
Principal investigator 1 PFIZER INC. $1,397.00 11/26/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130974546
Principal investigator 1 PFIZER INC. $35,048.16 11/23/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130988521
Principal investigator 1 ModernaTX, Inc. $972.24 11/22/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153439
Principal investigator 1 PFIZER INC. $282,469.24 11/22/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130975089
Principal investigator 1 ModernaTX, Inc. $129.77 11/18/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147183919
Principal investigator 1 ModernaTX, Inc. $9,050.00 11/15/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153433
Principal investigator 1 PFIZER INC. $154,667.41 11/05/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130988527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171437
Principal investigator 1 ModernaTX, Inc. $204.90 10/31/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147153457
Principal investigator 1 ModernaTX, Inc. $1,105.00 10/30/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153423
Principal investigator 1 ModernaTX, Inc. $442.00 10/30/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153425
Principal investigator 1 PFIZER INC. $11,293.00 10/30/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130998519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 10/28/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 10/28/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148097
Principal investigator 1 ModernaTX, Inc. $82,323.36 10/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153413
Principal investigator 1 ModernaTX, Inc. $8,730.20 10/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153415
Principal investigator 1 ModernaTX, Inc. $39.52 10/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153417
Principal investigator 1 ModernaTX, Inc. $2,844.20 10/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153419
Principal investigator 1 ModernaTX, Inc. $39.52 10/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147153421
Principal investigator 1 ModernaTX, Inc. $204.90 10/24/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147153451
Principal investigator 1 PFIZER INC. $56,173.64 10/24/2024 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1130998525
Principal investigator 1 ModernaTX, Inc. $102.45 10/22/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147153453
Principal investigator 1 PFIZER INC. $2,360.00 10/21/2024 Non-covered Recipient Entity
Res Cntrs of America HLWD
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130913195
Principal investigator 1 GlaxoSmithKline, LLC. $8,998.72 10/18/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1127529737
Principal investigator 1 Mylan Technologies Inc. $184,508.75 10/16/2024 Non-covered Recipient Entity
Research Centers of America, LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134076015
Principal investigator 1 ModernaTX, Inc. $8,650.00 10/14/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147153431
Principal investigator 1 ModernaTX, Inc. $47,196.00 10/09/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153427
Principal investigator 1 ModernaTX, Inc. $24,840.00 10/09/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153429
Principal investigator 1 Mylan Technologies Inc. $8,000.00 10/07/2024 Non-covered Recipient Entity
Research Centers of America, LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134076017
Principal investigator 1 PFIZER INC. $196,503.31 10/05/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130994669
Principal investigator 1 PFIZER INC. $1,350.40 10/05/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1130998530
Principal investigator 1 PFIZER INC. $1,348.75 10/05/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130998626
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 10/02/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 10/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 10/02/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 10/02/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 10/02/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 10/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 10/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148095
Principal investigator 1 PFIZER INC. $1,475.00 10/02/2024 Non-covered Recipient Entity
Res Cntrs of America HLWD
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130912746
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171201
Principal investigator 1 PFIZER INC. $1,475.00 09/30/2024 Non-covered Recipient Entity
Res Cntrs of America HLWD
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130913188
Principal investigator 1 ModernaTX, Inc. $35,580.60 09/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153409
Principal investigator 1 ModernaTX, Inc. $9,025.02 09/25/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153405
Principal investigator 1 PFIZER INC. $3,620.70 09/25/2024 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131012217
Principal investigator 1 PFIZER INC. $6,743.75 09/25/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131012222
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,768.30 09/20/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148039
Principal investigator 1 ModernaTX, Inc. $399.12 09/20/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147153455
Principal investigator 1 ModernaTX, Inc. $46,985.40 09/18/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153407
Principal investigator 1 PFIZER INC. $8,073.50 09/14/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1131012135
Principal investigator 1 Novavax Inc $2,960.37 09/12/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1123376061
Principal investigator 1 PFIZER INC. $1,180.00 09/09/2024 Non-covered Recipient Entity
Res Cntrs of America HLWD
A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130913191
Principal investigator 1 ModernaTX, Inc. $68,700.25 09/05/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1147153411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,262.00 09/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 09/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 09/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 09/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 09/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,314.00 09/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $510.00 09/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $902.00 09/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148053
Principal investigator 1 PFIZER INC. $47,764.78 09/04/2024 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131012129
Principal investigator 1 ModernaTX, Inc. $94,589.82 09/02/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171211
Principal investigator 1 ModernaTX, Inc. $77,522.40 08/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153397
Principal investigator 1 ModernaTX, Inc. $9,193.08 08/26/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1147153401
Principal investigator 1 PFIZER INC. $69,291.60 08/23/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1131033098
Principal investigator 1 PFIZER INC. $12,889.60 08/22/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1131033105
Principal investigator 1 PFIZER INC. $500.00 08/22/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1131033341
Principal investigator 1 ModernaTX, Inc. $598.68 08/20/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147183917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/18/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 08/14/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148067
Principal investigator 1 ModernaTX, Inc. $428.10 08/12/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147153337
Principal investigator 1 ModernaTX, Inc. $5,556.75 08/08/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147153335
Principal investigator 1 ModernaTX, Inc. $19,237.50 08/08/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147153399
Principal investigator 1 PFIZER INC. $31,733.82 08/06/2024 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131033347
Principal investigator 1 PFIZER INC. $20,272.46 08/02/2024 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131033530
Principal investigator 1 ModernaTX, Inc. $2,012.85 08/01/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171215
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171227
Principal investigator 1 ModernaTX, Inc. $42,700.50 07/29/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153261
Principal investigator 1 PFIZER INC. $387,302.40 07/26/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1131042556
Principal investigator 1 ModernaTX, Inc. $375.00 07/24/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147183817
Principal investigator 1 GlaxoSmithKline, LLC. $9,102.72 07/19/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1127529741
Principal investigator 1 Mylan Technologies Inc. $516,119.50 07/19/2024 Non-covered Recipient Entity
Research Centers of America, LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134076013
Principal investigator 1 PFIZER INC. $8,407.73 07/19/2024 Non-covered Recipient Entity
Research Centers of America LLC
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131043617
Principal investigator 1 ModernaTX, Inc. $4,080.00 07/18/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1147153267
Principal investigator 1 PFIZER INC. $12,289.62 07/16/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1131042544
Principal investigator 1 PFIZER INC. $438,155.41 07/16/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1131042550
Principal investigator 1 PFIZER INC. $14.10 07/15/2024 Non-covered Recipient Entity
Research Centers of America Hollywood
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130957425
Principal investigator 1 ModernaTX, Inc. $12,532.83 07/11/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147153257
Principal investigator 1 PFIZER INC. $3,412.80 07/09/2024 Non-covered Recipient Entity
Research Centers of America
A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1130918703
Principal investigator 1 ModernaTX, Inc. $3,908.60 07/05/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147153265
Principal investigator 1 ModernaTX, Inc. $201,442.44 07/04/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1147153263
Principal investigator 1 PFIZER INC. $115,403.90 07/02/2024 Non-covered Recipient Entity
Research Centers of America LLC
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131042527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 07/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148071
Principal investigator 1 ModernaTX, Inc. $149,883.31 07/01/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153259
Principal investigator 1 PFIZER INC. $5,266.98 06/29/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1131060181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171169
Principal investigator 1 ModernaTX, Inc. $3,118.98 06/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1147153321
Principal investigator 1 ModernaTX, Inc. $25,896.24 06/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153327
Principal investigator 1 PFIZER INC. $7,446.00 06/25/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131060186
Principal investigator 1 SANOFI PASTEUR INC. $1,920.00 06/21/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128701942
Principal investigator 1 SANOFI PASTEUR INC. $500.00 06/21/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128701944
Principal investigator 1 SANOFI PASTEUR INC. $5,462.64 06/21/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128701952
Principal investigator 1 PFIZER INC. $3,497.00 06/19/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131067717
Principal investigator 1 PFIZER INC. $18,000.00 06/18/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1131060190
Principal investigator 1 PFIZER INC. $159.60 06/15/2024 Non-covered Recipient Entity
Research Centers of America LLC
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131065934
Principal investigator 1 ModernaTX, Inc. $11,342.55 06/12/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147153325
Principal investigator 1 PFIZER INC. $31,113.90 06/11/2024 Non-covered Recipient Entity
Research Centers of America LLC
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131069844
Principal investigator 1 ModernaTX, Inc. $7,800.00 06/10/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147153323
Principal investigator 1 PFIZER INC. $127.52 06/10/2024 Non-covered Recipient Entity
Research Centers of America
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131017041
Principal investigator 1 PFIZER INC. $336.15 06/10/2024 Non-covered Recipient Entity
Research Centers of America
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131017047
Principal investigator 1 ModernaTX, Inc. $8,239.72 06/07/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147153333
Principal investigator 1 ModernaTX, Inc. $5,058.00 06/05/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147153331
Principal investigator 1 Alnylam Pharmaceuticals Inc. $562.55 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,539.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,539.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,813.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,539.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,539.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,539.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,539.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,539.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,539.00 06/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121148033
Principal investigator 1 ModernaTX, Inc. $2,003.82 06/03/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171113
Principal investigator 1 Mylan Technologies Inc. $18,000.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America, LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134076005
Principal investigator 1 Mylan Technologies Inc. $5,100.00 05/31/2024 Non-covered Recipient Entity
Research Centers of America, LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134076007
Principal investigator 1 SANOFI PASTEUR INC. $1,493.23 05/30/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701922
Principal investigator 1 ModernaTX, Inc. $1,664.28 05/29/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153311
Principal investigator 1 ModernaTX, Inc. $5,845.51 05/29/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183807
Principal investigator 1 ModernaTX, Inc. $1,607.10 05/29/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183809
Principal investigator 1 SANOFI PASTEUR INC. $4,599.45 05/29/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701938
Principal investigator 1 PFIZER INC. $637.60 05/28/2024 Non-covered Recipient Entity
Research Centers of America
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131017031
Principal investigator 1 PFIZER INC. $672.30 05/28/2024 Non-covered Recipient Entity
Research Centers of America
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131017035
Principal investigator 1 ModernaTX, Inc. $9,356.94 05/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1147153309
Principal investigator 1 ModernaTX, Inc. $311,835.30 05/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153317
Principal investigator 1 ModernaTX, Inc. $26,803.40 05/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1147153319
Principal investigator 1 ModernaTX, Inc. $2,650.00 05/24/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153315
Principal investigator 1 SANOFI PASTEUR INC. $45,509.95 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701914
Principal investigator 1 SANOFI PASTEUR INC. $39,165.48 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701916
Principal investigator 1 SANOFI PASTEUR INC. $13,148.73 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701920
Principal investigator 1 SANOFI PASTEUR INC. $55,674.84 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701924
Principal investigator 1 SANOFI PASTEUR INC. $45,109.50 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701926
Principal investigator 1 SANOFI PASTEUR INC. $54,561.66 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701928
Principal investigator 1 SANOFI PASTEUR INC. $22,413.04 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701930
Principal investigator 1 SANOFI PASTEUR INC. $32,757.52 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701932
Principal investigator 1 SANOFI PASTEUR INC. $45,670.51 05/24/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701936
Principal investigator 1 ModernaTX, Inc. $10,116.00 05/23/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153313
Principal investigator 1 ModernaTX, Inc. $6,995.00 05/09/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153247
Principal investigator 1 ModernaTX, Inc. $6,450.00 05/06/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147153305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 05/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 05/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 05/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148017
Principal investigator 1 ModernaTX, Inc. $55,665.33 05/01/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1147153307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,430.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171053
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121171117
Principal investigator 1 ModernaTX, Inc. $378.52 04/26/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147183909
Principal investigator 1 PFIZER INC. $381.00 04/26/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131077521
Principal investigator 1 PFIZER INC. $1,000.00 04/26/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1131088843
Principal investigator 1 ModernaTX, Inc. $45.00 04/23/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147183907
Principal investigator 1 ModernaTX, Inc. $400.00 04/19/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147153299
Principal investigator 1 SANOFI PASTEUR INC. $1,362.01 04/19/2024 Non-covered Recipient Entity
Research Centers Of America,llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128701918
Principal investigator 1 GlaxoSmithKline, LLC. $2,226.60 04/17/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1127526980
Principal investigator 1 GlaxoSmithKline, LLC. $27,649.49 04/17/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1127529739
Principal investigator 1 PFIZER INC. $2,500.00 04/17/2024 Non-covered Recipient Entity
Research Centers of America LLC
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131088855
Principal investigator 1 SANOFI PASTEUR INC. $52,474.60 04/17/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1128701934
Principal investigator 1 ModernaTX, Inc. $3,750.00 04/15/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153301
Principal investigator 1 PFIZER INC. $4,266.00 04/15/2024 Non-covered Recipient Entity
Rseearch Centers of America Hollywood
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1130916859
Principal investigator 1 SANOFI PASTEUR INC. $44,594.05 04/15/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1128701940
Principal investigator 1 GlaxoSmithKline, LLC. $1,550.09 04/12/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES No dispute reported 06/30/2026 1127529743
Principal investigator 1 PFIZER INC. $4,000.00 04/10/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131088849
Principal investigator 1 PFIZER INC. $18,648.18 04/09/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131077527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 04/05/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 04/05/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 04/05/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171083
Principal investigator 1 PFIZER INC. $1,286.70 04/05/2024 Non-covered Recipient Entity
Research Centers of America LLC
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131085897
Principal investigator 1 PFIZER INC. $750.00 04/05/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131085902
Principal investigator 1 BioNTech SE $1,920.90 04/04/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
BNT162-21 No dispute reported 06/30/2026 1150661454
Principal investigator 1 ModernaTX, Inc. $5,200.00 04/04/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147153303
Principal investigator 1 ModernaTX, Inc. $45.00 04/03/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147183905
Principal investigator 1 PFIZER INC. $42,689.52 04/03/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131086083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 04/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,976.00 04/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,976.00 04/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 04/01/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121148021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170969
Principal investigator 1 H. Lundbeck A S $2,367.50 03/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
STUDY WITH LU AF87908 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1145886466
Principal investigator 1 ModernaTX, Inc. $3,800.00 03/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147153279
Principal investigator 1 ModernaTX, Inc. $5,824.98 03/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153289
Principal investigator 1 ModernaTX, Inc. $15,454.80 03/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153293
Principal investigator 1 ModernaTX, Inc. $3,680.00 03/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1147153297
Principal investigator 1 PFIZER INC. $14,320.84 03/28/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131094999
Principal investigator 1 ModernaTX, Inc. $5,970.00 03/27/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147153295
Principal investigator 1 SANOFI PASTEUR INC. $45,010.42 03/25/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128697598
Principal investigator 1 SANOFI PASTEUR INC. $10,065.15 03/22/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128697578
Principal investigator 1 ModernaTX, Inc. $37,136.27 03/21/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147153277
Principal investigator 1 ModernaTX, Inc. $46,400.25 03/21/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1147153283
Principal investigator 1 ModernaTX, Inc. $4,317.57 03/21/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147153285
Principal investigator 1 ModernaTX, Inc. $6,734.88 03/21/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153287
Principal investigator 1 ModernaTX, Inc. $296,010.66 03/21/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age No dispute reported 06/30/2026 1147153291
Principal investigator 1 Novavax Inc $4,800.00 03/21/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1123376609
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 03/18/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128697582
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 03/13/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 03/13/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 03/13/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170853
Principal investigator 1 Merck Sharp & Dohme LLC $170,727.80 03/13/2024 Non-covered Recipient Entity
Research Centers of America Hollywood
An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Molnupiravir MK-4482 in Participants with Moderate Hepatic Impairment No dispute reported 06/30/2026 1136418899
Principal investigator 1 SANOFI PASTEUR INC. $1,800.00 03/13/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128697584
Principal investigator 1 SANOFI PASTEUR INC. $7,250.00 03/13/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128697588
Principal investigator 1 SANOFI PASTEUR INC. $1,750.00 03/13/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1128697602
Principal investigator 1 SANOFI PASTEUR INC. $9,050.00 03/13/2024 Non-covered Recipient Entity
Research Centers Of America,llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128701912
Principal investigator 1 SANOFI PASTEUR INC. $400.00 03/12/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128697580
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,976.00 03/08/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147685
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,976.00 03/08/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147827
Principal investigator 1 ModernaTX, Inc. $1,250.00 03/08/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183795
Principal investigator 1 ModernaTX, Inc. $2,250.00 03/08/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183797
Principal investigator 1 ModernaTX, Inc. $569.00 03/08/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183799
Principal investigator 1 BioNTech SE $1,920.90 03/07/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
BNT162-21 No dispute reported 06/30/2026 1150661448
Principal investigator 1 ModernaTX, Inc. $36,828.12 03/06/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1147153281
Principal investigator 1 ModernaTX, Inc. $1,600.00 03/06/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183791
Principal investigator 1 PFIZER INC. $5,000.00 03/06/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1131095017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,269.00 03/04/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147849
Principal investigator 1 ModernaTX, Inc. $375.00 03/01/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183789
Principal investigator 1 ModernaTX, Inc. $5,360.00 03/01/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147969
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147983
Principal investigator 1 BioNTech SE $1,920.90 02/29/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
BNT162-21 No dispute reported 06/30/2026 1150661446
Principal investigator 1 ModernaTX, Inc. $7,840.80 02/29/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147153275
Principal investigator 1 SANOFI PASTEUR INC. $3,500.00 02/29/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older No dispute reported 06/30/2026 1128697604
Principal investigator 1 ModernaTX, Inc. $1,947.51 02/28/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147153271
Principal investigator 1 ModernaTX, Inc. $3,754.89 02/26/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153273
Principal investigator 1 Novavax Inc $400.00 02/22/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1123374445
Principal investigator 1 Novavax Inc $267.30 02/22/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1123376059
Principal investigator 1 Novavax Inc $1,000.00 02/22/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1123376607
Principal investigator 1 Novavax Inc $2,792.00 02/22/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1123377713
Principal investigator 1 Novavax Inc $1,050.00 02/22/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 No dispute reported 06/30/2026 1123377715
Principal investigator 1 ModernaTX, Inc. $2,680.00 02/21/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147183785
Principal investigator 1 PFIZER INC. $1,850.00 02/14/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131095047
Principal investigator 1 BioNTech SE $1,500.00 02/13/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
BNT162-21 No dispute reported 06/30/2026 1150661450
Principal investigator 1 SANOFI PASTEUR INC. $18,193.00 02/09/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128697592
Principal investigator 1 Mylan Technologies Inc. $20,000.00 02/06/2024 Non-covered Recipient Entity
Research Centers of America, LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134076011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147667
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,976.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147673
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,001.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147695
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,976.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,976.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,976.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,565.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,001.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,001.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,488.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,013.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,322.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,127.00 02/02/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147925
Principal investigator 1 ModernaTX, Inc. $885.30 02/02/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147183787
Principal investigator 1 ModernaTX, Inc. $45,493.56 02/01/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age No dispute reported 06/30/2026 1147153269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Research Centers of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170907
Principal investigator 1 SANOFI PASTEUR INC. $480.00 01/30/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128697594
Principal investigator 1 SANOFI PASTEUR INC. $130.00 01/30/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128697600
Principal investigator 1 ModernaTX, Inc. $7,392.33 01/29/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147153249
Principal investigator 1 SANOFI PASTEUR INC. $11,340.00 01/26/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128697590
Principal investigator 1 ModernaTX, Inc. $3,917.42 01/25/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults No dispute reported 06/30/2026 1147153255
Principal investigator 1 Mylan Technologies Inc. $59.79 01/24/2024 Non-covered Recipient Entity
Research Centers of America, LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134076009
Principal investigator 1 SANOFI PASTEUR INC. $25,720.24 01/24/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128697596
Principal investigator 1 PFIZER INC. $4,500.00 01/23/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1131106605
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 01/22/2024 Non-covered Recipient Entity
Research Centers Of America,LLC
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128697586
Principal investigator 1 ModernaTX, Inc. $3,386.70 01/18/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age No dispute reported 06/30/2026 1147153251
Principal investigator 1 ModernaTX, Inc. $20,008.40 01/17/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183755
Principal investigator 1 ModernaTX, Inc. $2,160.00 01/17/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147183757
Principal investigator 1 ModernaTX, Inc. $5,335.20 01/17/2024 Non-covered Recipient Entity
CENEXEL CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147183759
Principal investigator 1 ModernaTX, Inc. $18,115.65 01/16/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153253
Principal investigator 1 ModernaTX, Inc. $375.00 01/16/2024 Non-covered Recipient Entity
CenExel RCA
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147182841
Principal investigator 1 H. Lundbeck A S $12,400.00 01/11/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
STUDY WITH LU AF87908 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1145886096
Principal investigator 1 PFIZER INC. $26,417.55 01/09/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131107072
Principal investigator 1 PFIZER INC. $9,167.00 01/09/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131110024
Principal investigator 1 Mylan Technologies Inc. $12,720.00 01/08/2024 Non-covered Recipient Entity
CenExel Clinical Research Inc
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134075935
Principal investigator 1 BioNTech SE $1,340.00 01/05/2024 Non-covered Recipient Entity
RESEARCH CENTERS OF AMERICA LLC
BNT162-21 No dispute reported 06/30/2026 1150661452
Principal investigator 1 PFIZER INC. $17,556.60 01/04/2024 Non-covered Recipient Entity
Research Centers of America LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1131107178
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 01/03/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $165.00 01/03/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,094.00 01/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,001.00 01/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,001.00 01/03/2024 Non-covered Recipient Entity
Research Centers Of America
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121147815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 01/03/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 01/03/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,293.00 01/03/2024 Non-covered Recipient Entity
Research Centers Of America
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121147825
Principal investigator 1 Mylan Technologies Inc. $660.00 01/02/2024 Non-covered Recipient Entity
CenExel Clinical Research Inc
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134075937
Principal investigator 1 Mylan Technologies Inc. $3,180.00 01/02/2024 Non-covered Recipient Entity
CenExel Clinical Research Inc
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134075939